The stock of RadNet (NAS:RDNT, 30-year Financials) appears to be significantly overvalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher. At its current price of $34.59 per share and the market cap of $1.8 billion, RadNet stock appears to be significantly overvalued. GF Value for RadNet is shown in the chart below.
Because RadNet is significantly overvalued, the long-term return of its stock is likely to be much lower than its future business growth, which averaged 2.7% over the past five years.
Link: These companies may deliever higher future returns at reduced risk.
Companies with poor financial strength offer investors a high risk of permanent capital loss. To avoid permanent capital loss, an investor must do their research and review a company’s financial strength before deciding to purchase shares. Both the cash-to-debt ratio and interest coverage of a company are a great way to to understand its financial strength. RadNet has a cash-to-debt ratio of 0.03, which which ranks in the bottom 10% of the companies in the industry of Medical Diagnostics & Research. The overall financial strength of RadNet is 3 out of 10, which indicates that the financial strength of RadNet is poor. This is the debt and cash of RadNet over the past years:
Investing in profitable companies carries less risk, especially in companies that have demonstrated consistent profitability over the long term. Typically, a company with high profit margins offers better performance potential than a company with low profit margins. RadNet has been profitable 9 years over the past 10 years. During the past 12 months, the company had revenues of $1.1 billion and earnings of $0.2 a share. Its operating margin of 6.32% in the middle range of the companies in the industry of Medical Diagnostics & Research. Overall, GuruFocus ranks RadNet’s profitability as fair. This is the revenue and net income of RadNet over the past years:
Growth is probably the most important factor in the valuation of a company. GuruFocus research has found that growth is closely correlated with the long term performance of a company’s stock. The faster a company is growing, the more likely it is to be creating value for shareholders, especially if the growth is profitable. The 3-year average annual revenue growth rate of RadNet is 2.7%, which ranks in the middle range of the companies in the industry of Medical Diagnostics & Research. The 3-year average EBITDA growth rate is 11.6%, which ranks in the middle range of the companies in the industry of Medical Diagnostics & Research.
One can also evaluate a company’s profitability by comparing its return on invested capital (ROIC) to its weighted average cost of capital (WACC). Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. If the return on invested capital exceeds the weighted average cost of capital, the company is likely creating value for its shareholders. During the past 12 months, RadNet’s ROIC is 3.11 while its WACC came in at 10.49. The historical ROIC vs WACC comparison of RadNet is shown below:
In summary, the stock of RadNet (NAS:RDNT, 30-year Financials) is believed to be significantly overvalued. The company's financial condition is poor and its profitability is fair. Its growth ranks in the middle range of the companies in the industry of Medical Diagnostics & Research. To learn more about RadNet stock, you can check out its 30-year Financials here.
To find out the high quality companies that may deliever above average returns, please check out GuruFocus High Quality Low Capex Screener.
